ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Project: Research

Project Details

StatusActive
Effective start/end date8/07/217/07/26

Keywords

  • treatment safety
  • treatment efficacy
  • prostate cancer
  • Randomised clinical trial